Suppr超能文献

AMBU® AuraGain™ 和 LMA® Supreme™ 在腹腔镜手术中的通气性能:一项随机对照试验。

Ventilatory performance of AMBU® AuraGain™ and LMA® Supreme™ in laparoscopic surgery: A randomised controlled trial.

机构信息

Department of Anaesthesiology, Intensive Care and Pain Medicine, Tan Tock Seng Hospital, Singapore.

Wendy Teoh Pte. Ltd., Private Anaesthesia Practice, Singapore.

出版信息

Anaesth Intensive Care. 2021 Sep;49(5):395-403. doi: 10.1177/0310057X211030521. Epub 2021 Sep 22.

Abstract

The Ambu® AuraGain™ (Ambu A/S, Ballerup, Denmark) is a newer phthalate-free, single-use supraglottic device with the advantage of a facility for tracheal intubation if necessary intraoperatively. We compared the oropharyngeal leak pressures and other performance variables between the AMBU AuraGain and the LMA® Supreme™ (Teleflex Medical, Athlone, Co. Westmeath, Ireland) in patients undergoing laparoscopic cholecystectomy and preperitoneoscopic inguinal herniorrhaphy with carbon dioxide insufflation under controlled ventilation. We recruited 120 American Society of Anesthesiologists physical status class I-3 patients between the ages of 21 and 80 years undergoing laparoscopic cholecystectomy or preperitoneoscopic inguinal herniorrhaphy into this single-centre randomised controlled trial. The primary outcome measure was the oropharyngeal leak pressures. Secondary outcomes included insertion parameters, ventilatory characteristics and postoperative sequelae. The AuraGain had slightly but significantly higher oropharyngeal leak pressures than the LMA Supreme (mean (standard deviation) 26.1 (6.9) versus 21.4 4.7) cmHO,  < 0.010). The overall insertion success of the AuraGain was comparable to the LMA Supreme (AuraGain 58/60 (96.7%); LMA Supreme 56/59 (94.9%),  = 0.679). The AuraGain was deemed more difficult to insert than the LMA Supreme, with 26/60 (43.3%) of AuraGain insertions graded easy versus 48/59 (81.4%) of LMA Supreme,  < 0.001. The mean time to insertion of the AuraGain was slightly longer than the LMA Supreme, 32.2 (10.5) versus 28.3 (12.0) s,  < 0.001. Intraoperative device failure occurred following carbon dioxide insufflation in one AuraGain and three LMA Supremes, bringing the perioperative success rate of AuraGain and LMA Supreme to 95% and 89.8%, respectively,  = 0.322. No cases of regurgitation and aspiration occurred, and minor postoperative complications were similar. The AuraGain exhibited higher oropharyngeal leak pressures than the LMA Supreme, but was slightly more difficult to insert. The higher oropharyngeal leak pressures suggest that ventilation might be less affected by high peak inspiratory pressures when using the AuraGain than the LMA Supreme.

摘要

Ambu® AuraGain™(丹麦 Ambu A/S)是一种新型的无邻苯二甲酸酯、一次性使用的声门上通气设备,如果需要,它具有在术中进行气管插管的优势。我们比较了腹腔镜胆囊切除术和二氧化碳气腹下前腹腔镜腹股沟疝修补术患者的气道漏气压和其他性能变量,研究对象为美国麻醉医师协会(ASA)身体状况 I-3 级的 120 名年龄在 21 至 80 岁之间的患者。这些患者被随机分为两组,分别使用 AMBU AuraGain 和 LMA® Supreme™(爱尔兰特莱弗医疗公司)。主要观察指标是气道漏气压。次要观察指标包括插入参数、通气特性和术后并发症。AuraGain 的气道漏气压略高于 LMA Supreme(分别为 26.1(6.9)cmH2O 和 21.4(4.7)cmH2O,  < 0.010)。AuraGain 的总体插入成功率与 LMA Supreme 相当(AuraGain 58/60(96.7%);LMA Supreme 56/59(94.9%),  = 0.679)。与 LMA Supreme 相比,AuraGain 插入难度更大,60 例 AuraGain 中有 26 例(43.3%)被评为容易,而 59 例 LMA Supreme 中有 48 例(81.4%),  < 0.001。AuraGain 的插入时间略长于 LMA Supreme,分别为 32.2(10.5)s 和 28.3(12.0)s,  < 0.001。在二氧化碳气腹充气后,一个 AuraGain 和三个 LMA Supreme 出现了设备故障,导致 AuraGain 和 LMA Supreme 的围手术期成功率分别为 95%和 89.8%,  = 0.322。没有发生反流和误吸,术后轻微并发症也相似。AuraGain 的气道漏气压高于 LMA Supreme,但插入难度略大。较高的气道漏气压表明,与 LMA Supreme 相比,使用 AuraGain 时,通气可能受高吸气峰压的影响较小。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验